EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment
EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.
EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.
What's Your Reaction?
